Our leadership team has extensive experience in developing, obtaining regulatory approvals for and successfully commercializing a variety of oncology products. In total, they have decades of combined experience spanning a range of cancers and other diseases.

Mary Lynne Hedley, Ph.D.

President, Chief Operating Officer

Mary Lynne Hedley, Ph.D. has served as our President and as a member of our board of directors since co-founding TESARO in March 2010. From July 2009 to February 2010, Dr. Hedley served as Executive Vice President of Operations and Chief Scientific Officer of Abraxis BioScience, a biotechnology company. Dr. Hedley served as Executive Vice President of Eisai Corporation of North America from January 2008 until July 2009, following the company's acquisition of MGI PHARMA in January 2008. Dr. Hedley served in various positions at MGI PHARMA from 2004 through its acquisition in January 2008, most recently as Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Hedley co-founded and served as the President and Chief Executive Officer of ZYCOS, a biotechnology company, which was acquired by MGI PHARMA in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University and earned her bachelor of science degree in microbiology from Purdue University and her doctoral degree in immunology from the University of Texas, Southwestern Medical Center. She mentors undergraduate science students at Harvard University and Boston University and also serves on the Boards of Directors of bluebird bio, Millendo Therapeutics and Youville Place, an assisted living facility. She served on the Board of Directors for Receptos until its acquisition by Celgene.